(Q35548766)

English

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

scientific article published on 10 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? (English)

1 reference

Europe PubMed Central

8 August 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

11

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

8 August 2017

Srdan Verstovsek

5

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

8 August 2017

Jorge Eduardo Cortes

1

object named as

Jorge Cortes

1 reference

Europe PubMed Central

8 August 2017

4

object named as

Susan O'Brien

1 reference

Europe PubMed Central

8 August 2017

Alfonso Quintas-Cardama

2

object named as

Alfonso Quintas-Cardama

1 reference

Europe PubMed Central

8 August 2017

7

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

8 August 2017

3

object named as

Elias Jabbour

1 reference

Europe PubMed Central

8 August 2017

Gautam Borthakur

6

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

8 August 2017

Guillermo Garcia-Manero

8

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

8 August 2017

Jenny Pui Shan Wong

10

object named as

Jenny Shan

1 reference

Europe PubMed Central

8 August 2017

author name string

Elizabeth Burton

9

1 reference

Europe PubMed Central

8 August 2017

language of work or name

0 references

publication date

10 August 2011

1 reference

Europe PubMed Central

8 August 2017

Clinical Lymphoma, Myeloma & Leukemia

1 reference

Europe PubMed Central

8 August 2017

11

1 reference

Europe PubMed Central

8 August 2017

5

1 reference

Europe PubMed Central

8 August 2017

421-426

1 reference

Europe PubMed Central

8 August 2017

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

12 July 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

26 September 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

26 September 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

26 September 2018

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

26 September 2018

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

15 November 2018

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3215673

15 November 2018

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CLML.2011.06.009

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35548766&oldid=1856485956"